progesterone- progesterone capsule
nucare pharmaceuticals,inc. - progesterone (unii: 4g7ds2q64y) (progesterone - unii:4g7ds2q64y) - progesterone 100 mg - progesterone capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. they are also indicated for use in secondary amenorrhea. progesterone capsules should not be used in women with any of the following conditions: - progesterone capsules should not be used in patients with known hypersensitivity to itsingredients. progesterone capsules contain peanut oil and should never be used by patients allergic to peanuts. - undiagnosed abnormal genital bleeding. - known, suspected, or history of breast cancer. - active deep vein thrombosis, pulmonary embolism or history of these conditions. - active arterial thromboembolic disease (for example, stroke and myocardial infarction), or a history of these conditions. - known liver dysfunction or disease. - known or suspected pregnancy.
medroxyprogesterone acetate tablet
blenheim pharmacal, inc. - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate 5 mg - medroxyprogesterone acetate tablets usp are a progestin indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. medroxyprogesterone acetate tablets usp are also indicated to reduce the incidence of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving daily oral conjugated estrogens 0.625 mg tablets. medroxyprogesterone acetate tablets usp should not be used in women with any of the following conditions: - undiagnosed abnormal genital bleeding. - known, suspected, or history of cancer of the breast. - known or suspected estrogen- or progesterone-dependent neoplasia. - active deep vein thrombosis, pulmonary embolism or a history of these conditions. - active or recent (within the past year) arterial thromboembolic disease (for example, stroke and myocardial infarction). - known liver dysfunction or disease. - missed abortion. - as a diagnostic test for pregnancy. -
medroxyprogesterone acetate tablet
readymeds - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate 2.5 mg - medroxyprogesterone acetate tablets usp are a progestin indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. medroxyprogesterone acetate tablets usp are also indicated to reduce the incidence of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving daily oral conjugated estrogens 0.625 mg tablets. medroxyprogesterone acetate tablets usp should not be used in women with any of the following conditions: - undiagnosed abnormal genital bleeding. - known, suspected, or history of cancer of the breast. - known or suspected estrogen- or progesterone-dependent neoplasia. - active deep vein thrombosis, pulmonary embolism or a history of these conditions. - active or recent (within the past year) arterial thromboembolic disease (for example, stroke and myocardial infarction). - known liver dysfunction or disease. - missed abortion. - as a diagnostic test for pregnancy. -
medroxyprogesterone acetate tablet
dispensing solutions, inc. - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate 5 mg - medroxyprogesterone acetate tablets usp are a progestin indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. medroxyprogesterone acetate tablets usp are also indicated to reduce the incidence of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving daily oral conjugated estrogens 0.625 mg tablets. medroxyprogesterone acetate tablets usp should not be used in women with any of the following conditions: - undiagnosed abnormal genital bleeding. - known, suspected, or history of cancer of the breast. - known or suspected estrogen- or progesterone-dependent neoplasia. - active deep vein thrombosis, pulmonary embolism or a history of these conditions. - active or recent (within the past year) arterial thromboembolic disease (for example, stroke and myocardial infarction). - known liver dysfunction or disease. - missed abortion. - as a diagnostic test for pregnancy. -
medroxyprogesterone acetate tablet
aidarex pharmaceuticals llc - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate 2.5 mg - medroxyprogesterone acetate tablets usp are a progestin indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. medroxyprogesterone acetate tablets usp are also indicated to reduce the incidence of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving daily oral conjugated estrogens 0.625 mg tablets. medroxyprogesterone acetate tablets usp should not be used in women with any of the following conditions: - undiagnosed abnormal genital bleeding. - known, suspected, or history of cancer of the breast. - known or suspected estrogen- or progesterone-dependent neoplasia. - active deep vein thrombosis, pulmonary embolism or a history of these conditions. - active or recent (within the past year) arterial thromboembolic disease (for example, stroke and myocardial infarction). - known liver dysfunction or disease. - missed abortion. - as a diagnostic test for pregnancy. -
medroxyprogesterone acetate tablet
physicians total care, inc. - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone 2.5 mg - medroxyprogesterone acetate tablets contain a progestin indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. medroxyprogesterone acetate is also indicated to reduce the incidence of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving daily oral conjugated estrogens 0.625 mg tablets. mpa tablets should not be used in women with any of the following conditions: - undiagnosed abnormal genital bleeding - known, suspected, or history of cancer of the breast - known or suspected estrogen- or progesterone-dependent neoplasia - active deep vein thrombosis, pulmonary embolism or a history of these conditions - active or recent (within the past year) arterial thromboembolic disease (for example, stroke and myocardial infarction) - known liver dysfunction or disease - missed abortion - as a diagnostic test for pregnancy - known hypersensitivity to the ingredients of mpa
medroxyprogesterone acetate tablet
rebel distributors corp. - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate 10 mg - medroxyprogesterone acetate tablets are a progestin indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. medroxyprogesterone acetate tablets are also indicated to reduce the incidence of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving daily oral conjugated estrogens 0.625 mg tablets. medroxyprogesterone acetate should not be used in women with any of the following conditions: - undiagnosed abnormal genital bleeding. - known, suspected, or history of cancer of the breast. - known or suspected estrogen- or progesterone-dependent neoplasia. - active deep vein thrombosis, pulmonary embolism or a history of these conditions. - active or recent (within the past year) arterial thromboembolic disease (for example, stroke and myocardial infarction). - known liver dysfunction or disease. - missed abortion. - as a diagnostic test for pregnancy. - known hypersensitiv
medroxyprogesterone acetate tablet
pd-rx pharmaceuticals, inc. - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate 5 mg - medroxyprogesterone acetate tablets are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. they are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets. mpa tablets is contraindicated in women with any of the following conditions: - undiagnosed abnormal genital bleeding. - known, suspected, or history of breast cancer. - known or suspected estrogen- or progesterone-dependent neoplasia. - active dvt, pe, or a history of these conditions. - active arterial thromboembolic disease (for example, stroke and mi), or a history of these conditions. - known anaphylactic reaction or angioedema to mpa. - known liver impairment or disease. - known or suspected pregnancy.
medroxyprogesterone acetate tablet
redpharm drug, inc. - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate 10 mg - medroxyprogesterone acetate tablets usp are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. they are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets. medroxyprogesterone acetate is contraindicated in women with any of the following conditions: 1. undiagnosed abnormal genital bleeding. 2. known, suspected, or history of breast cancer. 3. known or suspected estrogen- or progesterone-dependent neoplasia. 4. active dvt, pe, or a history of these conditions 5. active arterial thromboembolic disease (for example, stroke and mi), or a history of these conditions. 6. known anaphylactic reaction or angioedema to medroxyprogesterone acetate. 7. known liver impairment or disease. 8. known
progesterone capsule
golden state medical supply, inc. - progesterone (unii: 4g7ds2q64y) (progesterone - unii:4g7ds2q64y) - progesterone 100 mg - progesterone capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. they are also indicated for use in secondary amenorrhea. progesterone capsules should not be used in women with any of the following conditions: 1. progesterone capsules should not be used in patients with known hypersensitivity to its ingredients. progesterone capsules contain peanut oil and should never be used by patients allergic to peanuts. 2. undiagnosed abnormal genital bleeding. 3. known, suspected, or history of breast cancer. 4. active deep vein thrombosis, pulmonary embolism or history of these conditions. 5. active arterial thromboembolic disease (for example, stroke and myocardial infarction), or a history of these conditions. 6. known liver dysfunction or disease. 7. known or suspected pregnancy.